Computer-aided drug discovery of c-Abl kinase inhibitors from plant compounds against chronic myeloid leukemia

References

• Abbas, Z., & Rehman, S. (2018). An overview of cancer treatment modalities. InTech. https://doi.org/10.5772/intechopen.76558
   Google Scholar
• Acharya, P. C., Shetty, S., Fernandes, C., Suares, D., Maheshwari, R., & Tekade, R. K. (2018). Preformulation in drug research and pharmaceutical product development. In R. K. Tekade (Ed.), Dosage Form Design Considerations. (pp. 1–55). Academic Press.
   Google Scholar
• Aldewachi, H., Al-Zidan, R. N., Conner, M. T., & Salman, M. M. (2021). High-throughput screening platforms in the discovery of novel drugs for neurodegenerative diseases. Bioengineering, 8(2), 30. https://doi.org/10.3390/bioengineering8020030
   PubMedGoogle Scholar
• Alpay, K., Farshchian, M., Tuomela, J., Sandholm, J., Aittokallio, K., Siljamäki, E., Kallio, M., Kähäri, V. M., & Hietanen, S. (2014). Inhibition of c-Abl kinase activity renders cancer cells highly sensitive to mitoxantrone. PloS One, 9(8), e105526. https://doi.org/10.1371/journal.pone.0105526
   PubMed Web of Science ®Google Scholar
• Alshehri, M. M., Danazumi, A. U., Kanan, M., Bello, R. O., Alghazwni, M. K., Alshehri, M., Alshlali, O. M., Umar, H. I., Alshlali, O. M., Isiyaku, H., & Repurposing, U. (2024). Repurposing the inhibitors of MMP-9 and SGLT-2 against ubiquitin specific protease 30 in Parkinson ’ s disease : Computational modelling studies. Journal of Biomolecular Structure & Dynamics, 42(3), 1307–1318. https://doi.org/10.1080/07391102.2023.2208223
   PubMed Web of Science ®Google Scholar
• Arber, D. A., Orazi, A., Hasserjian, R., Thiele, J., Borowitz, M. J., Le Beau, M. M., Bloomfield, C. D., Cazzola, M., & Vardiman, J. W. (2016). The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood, 127(20), 2391–2405. https://doi.org/10.1182/blood-2016-03-643544
   PubMed Web of Science ®Google Scholar
• Astalakshmi, D., T, G., K B, G. S., M, N., M R, H. H. S., S, G., Latha, D., & Kumar, D. (2022). Over view on molecular docking: A powerful approach for structure based drug discovery. International Journal of Pharmaceutical Sciences Review and Research, 77(2), 146–157. https://doi.org/10.47583/ijpsrr.2022.v77i02.029
   Google Scholar
• Aung, T. N., Qu, Z., Kortschak, R. D., & Adelson, D. L. (2017). Understanding the effectiveness of natural compound mixtures in cancer through their molecular mode of action. International Journal of Molecular Sciences, 18(3), 656. https://doi.org/10.3390/ijms18030656
   PubMed Web of Science ®Google Scholar
• Ayuba, A. M., & Umar, U. (2021). Modeling vitexin and isovitexin flavones as corrosion inhibitors for aluminium metal. Karbala International Journal of Modern Science, 7(3), 206–205. https://doi.org/10.33640/2405-609X.3119
   Google Scholar
• Aziz, M., Ejaz, S. A., Zargar, S., Akhtar, N., Aborode, A. T., A Wani, T., Batiha, G. E.-S., Siddique, F., Alqarni, M., & Akintola, A. A. (2022). Deep learning and structure-based virtual screening for drug discovery against NEK7: A novel target for the treatment of cancer. Molecules (Basel, Switzerland), 27(13), 4098. https://doi.org/10.3390/molecules27134098
   PubMed Web of Science ®Google Scholar
• Banks, W. A. (2009). Characteristics of compounds that cross the blood-brain barrier. BMC Neurology, 9 Suppl 1(SUPPL. 1), S3. https://doi.org/10.1186/1471-2377-9-S1-S3
   PubMedGoogle Scholar
• Barclay, P. L., & Zhang, D. Z. (2021). Periodic boundary conditions for arbitrary deformations in molecular dynamics simulations. Journal of Computational Physics, 435, 110238. https://doi.org/10.1016/j.jcp.2021.110238
   Web of Science ®Google Scholar
• Bello, R. O., Okunlola, S. T., Kumar, N., Victor, O., Jimoh, T. O., Abdulsalam, Z. N., Kehinde, I. O., & Umar, H. I. (2023). An integrative computational approach for the identification of dual inhibitors of isocitrate dehydrogenase 1 and 2 from phytocompounds of Phyllantus amarus. Journal of Biomolecular Structure and Dynamics. https://doi.org/10.1080/07391102.2023.2245494
   Web of Science ®Google Scholar
• Bendjeddou, A., Abbaz, T., Gouasmia, A., & Villemin, D. (2016). Molecular Structure, HOMO-LUMO, MEP and Fukui function analysis of some TTF-donor substituted molecules using DFT (B3LYP) calculations. International Research Journal of Pure and Applied Chemistry, 12(1), 1–9. https://doi.org/10.9734/IRJPAC/2016/27066
   Google Scholar
• Bergström, C. A. S., & Larsson, P. (2018). Computational prediction of drug solubility in water-based systems: Qualitative and quantitative approaches used in the current drug discovery and development setting. International Journal of Pharmaceutics, 540(1-2), 185–193. https://doi.org/10.1016/j.ijpharm.2018.01.044
   PubMed Web of Science ®Google Scholar
• Boral, N., Ghosh, P., Goswami, A., & Bhattacharyya, M. (2022). Accountable prediction of drug ADMET Properties with molecular descriptors. BioRxiv, 2, 1–11.
   Google Scholar
• Borges, C. D S., Ferreira, A. F., Almeida, V. H., Gomes, F. G., Berzoti-Coelho, M. G., Cacemiro, M. D C., Nunes, N. S., Figueiredo-Pontes, L. L., Simões, B. P., Castro, F. A., & Monteiro, R. Q. (2018). Crosstalk between BCR-ABL and protease-activated receptor 1 (PAR1) suggests a novel target in chronic myeloid leukemia. Experimental Hematology, 66(Im), 50–62. https://doi.org/10.1016/j.exphem.2018.07.008
   PubMedGoogle Scholar
• Bors, L., & Erdö, F. (2019). Overcoming the blood-brain barrier. Challenges and tricks for CNS drug delivery. Scientia Pharmaceutica, 87(1), 6. https://doi.org/10.3390/scipharm87010006
   Web of Science ®Google Scholar
• Cai, J., Liu, H., Chen, Y., Yu, J., Gao, J., Jiang, H., Zhai, X., Ju, X., Wu, X., Wang, N., Tian, X., Liang, C., Fang, Y., Zhou, F., Li, H., Sun, L., Yang, L., Guo, J., Liu, A., … Pui, C.-H. (2023). Effect of the tyrosine kinase inhibitors on the growth in children with Philadelphia chromosome – positive acute lymphoblastic leukemia: A case-control study. The Lancet Regional Health. Western Pacific, 38, 100818. https://doi.org/10.1016/j.lanwpc.2023.100818
   PubMedGoogle Scholar
• Cai, C., Tang, W., Qiao, C., Bao, B., Xie, P., Zhao, S., & Liu, H. (2022). A reaction density functional theory study of solvent effect in the nucleophilic addition reactions in aqueous solution. Green Energy & Environment, 7(4), 782–791. https://doi.org/10.1016/j.gee.2020.11.028
   Google Scholar
• Cavasotto, C. N., Aucar, M. G., & Adler, N. S. (2019). Computational chemistry in drug lead discovery and design. International Journal of Quantum Chemistry, 119(2), 1–19. https://doi.org/10.1002/qua.25678
   Web of Science ®Google Scholar
• Chow, S.-C. (2014). Bioavailability and bioequivalence in drug development. Interdisciplinary Sciences: Computational Life Sciences, 6(4), 304–320. https://doi.org/10.1002/wics.1310.Bioavailability
   Google Scholar
• Ciftci, H. I., Ozturk, S. E., Ali, T. F. S., Radwan, M. O., Tateishi, H., Koga, R., Ocak, Z., Can, M., Otsuka, M., & Fujita, M. (2018). The first pentacyclic triterpenoid gypsogenin derivative exhibiting anti-ABL1 kinase and anti-chronic myelogenous leukemia activities. Biological & Pharmaceutical Bulletin, 41(4), 570–574. https://doi.org/10.1248/bpb.b17-00902
   PubMed Web of Science ®Google Scholar
• Cruz-Vicente, P., Passarinha, L. A., Silvestre, S., & Gallardo, E. (2021). Recent developments in new therapeutic agents against Alzheimer and Parkinson’s diseases: In-silico approaches. Molecules (Basel, Switzerland), 26(8), 2193. https://doi.org/10.3390/molecules26082193
   PubMed Web of Science ®Google Scholar
• Daina, A., Michielin, O., & Zoete, V. (2017). SwissADME: A free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Scientific Reports, 7(1), 42717. https://doi.org/10.1038/srep42717
   PubMed Web of Science ®Google Scholar
• Danazumi, A. U., & Umar, H. I. (2023). You must be flexible enough to be trained, Mr. Dynamics simulator. Molecular Diversity, 0123456789, 5–7. https://doi.org/10.1007/s11030-023-10689-5
   Google Scholar
• Dar, A. M., & Mir, S. (2017). Molecular docking: Approaches, types, applications and basic challenges. Journal of Analytical & Bioanalytical Techniques, 08(02), 1–10. https://doi.org/10.4172/2155-9872.1000356
   Google Scholar
• de Oliveira, V. M., Estácio, S. P., da Silva Mendes, F. R., Campos, O. S., Marinho, M. M., & Marinho, E. S. (2020). Characterization of rotenoid stemonal by semiempirical methods and molecular docking. SN Applied Sciences, 2(4), 1–8. https://doi.org/10.1007/s42452-020-2346-7
   Web of Science ®Google Scholar
• do Carmo, A. L., Bettanin, F., Oliveira Almeida, M., Pantaleão, S. Q., Rodrigues, T., Homem-de-Mello, P., & Honorio, K. M. (2020). Competition between phenothiazines and BH3 peptide for the binding site of the antiapoptotic BCL-2 protein. Frontiers in Chemistry, 8(April), 235. https://doi.org/10.3389/fchem.2020.00235
   PubMedGoogle Scholar
• Druker, B. J., Guilhot, F., O'Brien, S. G., Gathmann, I., Kantarjian, H., Gattermann, N., Deininger, M. W. N., Silver, R. T., Goldman, J. M., Stone, R. M., Cervantes, F., Hochhaus, A., Powell, B. L., Gabrilove, J. L., Rousselot, P., Reiffers, J., Cornelissen, J. J., Hughes, T., Agis, H., … Larson, R. A. (2006). Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. The New England Journal of Medicine, 355(23), 2408–2417. https://doi.org/10.1056/NEJMoa062867
   PubMed Web of Science ®Google Scholar
• Du, X., Li, Y., Xia, Y. L., Ai, S. M., Liang, J., Sang, P., Ji, X. L., & Liu, S. Q. (2016). Insights into protein–ligand interactions: Mechanisms, models, and methods. International Journal of Molecular Sciences, 17(2), 144. https://doi.org/10.3390/ijms17020144
   PubMed Web of Science ®Google Scholar
• Du, Z., & Lovly, C. M. (2018). Mechanisms of receptor tyrosine kinase activation in cancer. Molecular Cancer, 17(1), 58. https://doi.org/10.1186/s12943-018-0782-4
   PubMed Web of Science ®Google Scholar
• Dumnicka, P., Góra-tybor, J., Sacha, T., Prejzner, W., Wasilewska, E., Kłoczko, J., Niesiob, J., Wasilewska, J., Ciepłuch, H., Makowska, W., Kopera, M., Wichary, R., Kroll-balcerzak, R., Swiniarska, M., Paczkowska, E., Biernat, M., Joks, M., Oller, M., Kasza, R., … Grzybowska-izydorczyk, O. (2022). The outcomes of ponatinib therapy in patients with chronic myeloid leukemia resistant or intolerant to previous tyrosine kinase inhibitors, treated in Poland within the donation program. Clinical Lymphoma, Myeloma and Leukemia, 22(6), 405–415. https://doi.org/10.1016/j.clml.2021.11.012
   PubMed Web of Science ®Google Scholar
• Ece, A. (2023). Computer‑aided drug design. BMC Chemistry, 17(1), 26. https://doi.org/10.1186/s13065-023-00939-w
   PubMed Web of Science ®Google Scholar
• Ejaz, S. A., Aziz, M., Zafar, Z., Akhtar, N., & Ogaly, H. A. (2023). Revisiting the inhibitory potential of protein kinase inhibitors against NEK7 protein via comprehensive computational investigations. Scientific Reports, 13(1), 4304. https://doi.org/10.1038/s41598-023-31499-7
   PubMed Web of Science ®Google Scholar
• Fadler, R. E., & Flood, A. H. (2022). Rigidity and flexibility in rotaxanes and their relatives; On being stubborn and easy-going. Frontiers in Chemistry, 10(April), 856173. https://doi.org/10.3389/fchem.2022.856173
   PubMedGoogle Scholar
• Flores-Holguín, N., Frau, J., & Glossman-Mitnik, D. (2021). In silico pharmacokinetics, ADMET study and conceptual DFT analysis of two plant cyclopeptides isolated from Rosaceae as a computational peptidology approach. Frontiers in Chemistry, 9(August), 708364. https://doi.org/10.3389/fchem.2021.708364
   PubMedGoogle Scholar
• Guan, L., Yang, H., Cai, Y., Sun, L., Di, P., Li, W., Liu, G., & Tang, Y. (2019). ADMET-score - A comprehensive scoring function for evaluation of chemical drug-likeness. MedChemComm, 10(1), 148–157. https://doi.org/10.1039/C8MD00472B
   PubMed Web of Science ®Google Scholar
• Guengerich, F. P. (2022). Inhibition of cytochrome P450 enzymes by drugs - Molecular basis and practical applications. Biomolecules & Therapeutics, 30(1), 1–18. https://doi.org/10.4062/biomolther.2021.102
   PubMed Web of Science ®Google Scholar
• Harder, E., Damm, W., Maple, J., Wu, C., Reboul, M., Xiang, J. Y., Wang, L., Lupyan, D., Dahlgren, M. K., Knight, J. L., Kaus, J. W., Cerutti, D. S., Krilov, G., Jorgensen, W. L., Abel, R., & Friesner, R. A. (2016). OPLS3: A force field providing broad coverage of drug-like small molecules and proteins. Journal of Chemical Theory and Computation, 12(1), 281–296. https://doi.org/10.1021/acs.jctc.5b00864
   PubMed Web of Science ®Google Scholar
• Hartmann, T., & Schmitt, J. (2004). Lipophilicity - Beyond octanol/water: A short comparison of modern technologies. Drug Discovery Today. Technologies, 1(4), 431–439. https://doi.org/10.1016/j.ddtec.2004.10.006
   PubMedGoogle Scholar
• He, B., Wang, Q., Liu, X., Lu, Z., Han, J., Pan, C., Carter, B. Z., Liu, Q., Xu, N., & Zhou, H. (2020). A novel HDAC inhibitor chidamide combined with imatinib synergistically targets tyrosine kinase inhibitor resistant chronic myeloid leukemia cells. Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie, 129(June), 110390. https://doi.org/10.1016/j.biopha.2020.110390
   PubMedGoogle Scholar
• Helms, H. C. C., Kristensen, M., Saaby, L., Fricker, G., & Brodin, B. (2022). Drug delivery strategies to overcome the blood–brain barrier (BBB). Handbook of Experimental Pharmacology, 273(9), 151–183. https://doi.org/10.1007/164_2020_403
   PubMedGoogle Scholar
• Hochhaus, A., Baccarani, M., Deininger, M., Apperley, J. F., Lipton, J. H., Goldberg, S. L., Corm, S., Shah, N. P., Cervantes, F., Silver, R. T., Niederwieser, D., Stone, R. M., Dombret, H., Larson, R. A., Roy, L., Hughes, T., Müller, M. C., Ezzeddine, R., Countouriotis, A. M., & Kantarjian, H. M. (2008). Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib. Leukemia, 22(6), 1200–1206. https://doi.org/10.1038/leu.2008.84
   PubMed Web of Science ®Google Scholar
• Hochhaus, A., Baccarani, M., Silver, R. T., Schiffer, C., Apperley, J. F., Cervantes, F., Clark, R. E., Cortes, J. E., Deininger, M. W., Guilhot, F., Hjorth-Hansen, H., Hughes, T. P., Janssen, J. J. W. M., Kantarjian, H. M., Kim, D. W., Larson, R. A., Lipton, J. H., Mahon, F. X., Mayer, J., … Hehlmann, R. (2020). European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia, 34(4), 966–984. https://doi.org/10.1038/s41375-020-0776-2
   PubMed Web of Science ®Google Scholar
• Hollingsworth, S. A., & Dror, R. O. (2018). Molecular dynamics simulation for all. Neuron, 99(6), 1129–1143. https://doi.org/10.1016/j.neuron.2018.08.011
   PubMed Web of Science ®Google Scholar
• Hoover, W. G. (1985). Canonical dynamics: Equilibrium phase-space distributions. Physical Review. A, General Physics, 31(3), 1695–1697. https://doi.org/10.1103/physreva.31.1695
   PubMedGoogle Scholar
• Hospital, A., Goñi, J. R., Orozco, M., & Gelpí, J. L. (2015). Molecular dynamics simulations: Advances and applications. Advances and Applications in Bioinformatics and Chemistry: AABC, 8(1), 37–47. https://doi.org/10.2147/AABC.S70333
   PubMedGoogle Scholar
• Hou, T., Wang, J., Zhang, W., & Xu, X. (2007). ADME evaluation in drug discovery. Can oral biavailability in humans be effectively predicted by simple molecular property-based rules? Journal of Chemical Information and Modeling, 47(2), 460–463. https://doi.org/10.1021/ci6003515
   PubMed Web of Science ®Google Scholar
• Hughes, J. P., Rees, S. S., Kalindjian, S. B., & Philpott, K. L. (2011). Principles of early drug discovery. British Journal of Pharmacology, 162(6), 1239–1249. https://doi.org/10.1111/j.1476-5381.2010.01127.x
   PubMed Web of Science ®Google Scholar
• Isabel, A., Pin, C., Villaverde, L., Martín, S., Milena, M., & Castro, S. (2023). The needs and medication experience of patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: A systematic review. Farmacia Hospitalaria, 47, 785–792. https://doi.org/10.1016/j.farma.2023.02.002
   Web of Science ®Google Scholar
• Ishiki, H. M., Maria, J., Filho, B., Silva, M. S., Scotti, M. T., & Scotti, L. (2018). Computer-aided drug design applied to Parkinson targets. Current Neuropharmacology, 16(6), 865–880. https://doi.org/10.2174/1570159X15666171128145423
   PubMed Web of Science ®Google Scholar
• Jia, C. Y., Li, J. Y., Hao, G. F., & Yang, G. F. (2020). A drug-likeness toolbox facilitates ADMET study in drug discovery. Drug Discovery Today, 25(1), 248–258. https://doi.org/10.1016/j.drudis.2019.10.014
   PubMed Web of Science ®Google Scholar
• Kaiser, T. M., Dentmon, Z. W., Dalloul, C. E., Sharma, S. K., & Liotta, D. C. (2020). Accelerated discovery of novel ponatinib analogs with improved properties for the treatment of Parkinson’s disease. ACS Medicinal Chemistry Letters, 11(4), 491–496. https://doi.org/10.1021/acsmedchemlett.9b00612
   PubMed Web of Science ®Google Scholar
• Kantarjian, H. M., Giles, F. J., Bhalla, K. N., Pinilla-Ibarz, J., Larson, R. A., Gattermann, N., Ottmann, O. G., Hochhaus, A., Radich, J. P., Saglio, G., Hughes, T. P., Martinelli, G., Kim, D. W., Shou, Y., Gallagher, N. J., Blakesley, R., Baccarani, M., Cortes, J., & Le Coutre, P. D. (2011). Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results. Blood, 117(4), 1141–1145. https://doi.org/10.1182/blood-2010-03-277152
   PubMed Web of Science ®Google Scholar
• Kantarjian, H., Giles, F., Wunderle, L., Bhalla, K., O'Brien, S., Wassmann, B., Tanaka, C., Manley, P., Rae, P., Mietlowski, W., Bochinski, K., Hochhaus, A., Griffin, J. D., Hoelzer, D., Albitar, M., Dugan, M., Cortes, J., Alland, L., & Ottmann, O. G. (2006). Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. The New England Journal of Medicine, 354(24), 2542–2551. https://doi.org/10.1056/NEJMoa055104
   PubMed Web of Science ®Google Scholar
• Kantarjian, H., Pasquini, R., Lévy, V., Jootar, S., Holowiecki, J., Hamerschlak, N., Hughes, T., Bleickardt, E., Dejardin, D., Cortes, J., & Shah, N. P. (2009). Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia resistant to imatinib at a dose of 400 to 600 milligrams daily: Two-year follow-up of a randomized phase 2 study (START-R). Cancer, 115(18), 4136–4147. https://doi.org/10.1002/cncr.24504
   PubMed Web of Science ®Google Scholar
• Kar, S., & Leszczynski, J. (2020). Open access in silico tools to predict the ADMET profiling of drug candidates. Expert Opinion on Drug Discovery, 15(12), 1473–1487. https://doi.org/10.1080/17460441.2020.1798926
   PubMed Web of Science ®Google Scholar
• Kenny, P. W. (2022). Hydrogen bond donors in drug design. Journal of Medicinal Chemistry, 65(21), 14261–14275. https://doi.org/10.1021/acs.jmedchem.2c01147
   PubMed Web of Science ®Google Scholar
• Khan, T., Ali, M., Khan, A., Nisar, P., Jan, S. A., Afridi, S., & Shinwari, Z. K. (2020). Anticancer plants: A review of the active phytochemicals, applications in animal models, and regulatory aspects. Biomolecules, 10(1), 1–30. https://doi.org/10.3390/biom10010047
   Web of Science ®Google Scholar
• Khazdair, M. R., Kianmehr, M., & Anaeigoudari, A. (2021). Effects of medicinal plants and flavonoids on Parkinson’s disease: A review on basic and clinical evidences. Tabriz University of Medical Sciences, 11(2), 224–232. https://doi.org/10.34172/apb.2021.026
   Google Scholar
• Kotsampasakou, E., Montanari, F., & Ecker, G. F. (2017). Predicting drug-induced liver injury: The importance of data curation. Toxicology, 389, 139–145. https://doi.org/10.1016/j.tox.2017.06.003
   PubMed Web of Science ®Google Scholar
• Kulkarni, A. M., Rampogu, S., & Lee, K. W. (2021). Computer-aided drug discovery identifies alkaloid inhibitors of Parkinson’s disease associated protein, prolyl oligopeptidase. Evidence-Based Complementary and Alternative Medicine: ECAM, 2021, 6687572–6687510. https://doi.org/10.1155/2021/6687572
   PubMed Web of Science ®Google Scholar
• Kumar, A., & Higdon, J. J. L. (2011). Particle mesh Ewald Stokesian dynamics simulations for suspensions of non-spherical particles. Journal of Fluid Mechanics, 675, 297–335. https://doi.org/10.1017/jfm.2011.18
   Web of Science ®Google Scholar
• Li, Y., Meng, Q., Yang, M., Liu, D., Hou, X., Tang, L., Wang, X., Lyu, Y., Chen, X., Liu, K., Yu, A. M., Zuo, Z., & Bi, H. (2019). Current trends in drug metabolism and pharmacokinetics. Acta Pharmaceutica Sinica. B, 9(6), 1113–1144. https://doi.org/10.1016/j.apsb.2019.10.001
   PubMed Web of Science ®Google Scholar
• Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (1997). Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Advanced Drug Delivery Reviews, 23(1-3), 3–25. https://doi.org/10.1016/S0169-409X(96)00423-1
   Web of Science ®Google Scholar
• Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (2001). Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Advanced Drug Delivery Reviews, 46(1-3), 3–26. https://doi.org/10.1016/j.addr.2012.09.019
   PubMed Web of Science ®Google Scholar
• Liu, Y., Jang, H., Zhang, M., Tsai, C., Maloney, R., & Nussinov, R. (2022). The structural basis of BCR-ABL recruitment of GRB2 in chronic myelogenous leukemia. Biophysical Journal, 121(12), 2251–2265. https://doi.org/10.1016/j.bpj.2022.05.030
   PubMed Web of Science ®Google Scholar
• Mahul-Mellier, A.-L., Fauvet, B., Gysbers, A., Dikiy, I., Oueslati, A., Georgeon, S., Lamontanara, A. J., Bisquertt, A., Eliezer, D., Masliah, E., Halliday, G., Hantschel, O., & Lashuel, H. A. & Hilal. (2014). c-Abl phosphorylates alpha-synuclein and regulates its degradation, implication for alpha-synuclein clearance and contribution to the pathogenesis of Parkinson’s disease. Human Molecular Genetics, 23(11), 2858–2879. https://doi.org/10.1093/hmg/ddt674
   PubMed Web of Science ®Google Scholar
• Mishra, C. B., Pandey, P., Sharma, R. D., Malik, M. Z., Mongre, R. K., Lynn, A. M., Prasad, R., Jeon, R., & Prakash, A. (2021). Identifying the natural polyphenol catechin as a multi-targeted agent against SARS-CoV-2 for the plausible therapy of COVID-19: An integrated computational approach. Briefings in Bioinformatics, 22(2), 1346–1360. https://doi.org/10.1093/bib/bbaa378
   PubMed Web of Science ®Google Scholar
• Mukhtar, M., Saleem, M., Nazir, M., Riaz, N., Shafiq, N., Saleem, H., Tauseef, S., Khan, S., Ehsan Mazhar, M., Bakhsh Tareen, R., Mahmood, M. H., Ur, R., Tousif, M. I., & Ojha, S. C. (2023). Identification of pyrrolizidine alkaloids and flavonoid glycosides through HR-LCMS/MS analysis, biological screening, DFT and molecular docking studies on Heliotropium dasycarpum Ledeb. Arabian Journal of Chemistry, 16(5), 104655. https://doi.org/10.1016/j.arabjc.2023.104655
   Web of Science ®Google Scholar
• Natarajan, A., Thangarajan, R., & Kesavan, S. (2019). Repurposing drugs by in silico methods to target BCR kinase domain in chronic myeloid leukemia. Asian Pacific Journal of Cancer Prevention: APJCP, 20(11), 3399–3406. https://doi.org/10.31557/APJCP.2019.20.11.3399
   PubMedGoogle Scholar
• Orio, M., Pantazis, D. A., & Neese, F. (2009). Density functional theory. Photosynthesis Research, 102(2-3), 443–453. https://doi.org/10.1007/s11120-009-9404-8
   PubMed Web of Science ®Google Scholar
• Patel, C. N., Kumar, S. P., Pandya, H. A., & Rawal, R. M. (2021). Identification of potential inhibitors of coronavirus hemagglutinin-esterase using molecular docking, molecular dynamics simulation and binding free energy calculation. Molecular Diversity, 25(1), 421–433. https://doi.org/10.1007/s11030-020-10135-w
   PubMed Web of Science ®Google Scholar
• Peverati, R., & Truhlar, D. G. (2014). Quest for a universal density functional: The accuracy of density functionals across a broad spectrum of databases in chemistry and physics. Philosophical Transactions. Series A, Mathematical, Physical, and Engineering Sciences, 372(2011), 20120476. https://doi.org/10.1098/rsta.2012.0476
   PubMed Web of Science ®Google Scholar
• Pophali, P. A., & Patnaik, M. M. (2016). The role of new tyrosine kinase inhibitors in chronic myeloid leukemia. Cancer Journal (Sudbury, Mass.), 22(1), 40–50. https://doi.org/10.1097/PPO.0000000000000165
   PubMed Web of Science ®Google Scholar
• Quy, P. T., My, T. T. A., Bui, T. Q., Loan, H. T. P., Van Anh, T. T., Triet, N. T., Quang, D. T., & Nhung, N. T. A. (2021). Molecular docking prediction of carvone and trans-geraniol inhibitability towards SARS-CoV-2. Vietnam Journal of Chemistry, 59(4), 457–466. https://doi.org/10.1002/vjch.202000175
   Google Scholar
• Rabiei, Z., Solati, K., & Amini-Khoei, H. (2019). Phytotherapy in treatment of Parkinson’s disease: A review. Pharmaceutical Biology, 57(1), 355–362. https://doi.org/10.1080/13880209.2019.1618344
   PubMed Web of Science ®Google Scholar
• Rahman, J., Tareq, A. M., Hossain, M. M., Sakib, S. A., Islam, M. N., Ali, M. H., Neshar Uddin, A. B. M., Hoque, M., Nasrin, M. S., Emran, T. B., Capasso, R., Ali Reza, A. S. M., & Simal-Gandara, J. (2020). Biological evaluation, DFT calculations and molecular docking studies on the antidepressant and cytotoxicity activities of Cycas pectinata Buch.-Ham. compounds. Pharmaceuticals (Basel, Switzerland), 13(9), 232. https://doi.org/10.3390/ph13090232
   PubMedGoogle Scholar
• Ren, Y., De Blanco, E. J. C., Fuchs, J. R., Soejarto, D. D., Burdette, J. E., Swanson, S. M., & Kinghorn, A. D. (2019). Potential anticancer agents characterized from selected tropical plants. Journal of Natural Products, 82(3), 657–679. https://doi.org/10.1021/acs.jnatprod.9b00018
   PubMed Web of Science ®Google Scholar
• Rossari, F., Minutolo, F., & Orciuolo, E. (2018). Past, present, and future of BCR-Abl inhibitors: From chemical development to clinical efficacy. Journal of Hematology & Oncology, 11(1), 84. https://doi.org/10.1186/s13045-018-0624-2
   PubMedGoogle Scholar
• Sadatmadani, S. F., Malakoutikhah, Z., Mohaghegh, F., Peikar, M., & Saboktakin, M. (2022). Nilotinib-induced elephantine psoriasis in a patient with chronic myeloid leukemia: A rare case report and literature review. Current Therapeutic Research, Clinical and Experimental, 96, 100676. https://doi.org/10.1016/j.curtheres.2022.100676
   PubMed Web of Science ®Google Scholar
• Sajvani, K. T., Gajjar, A. K., & Savjani, J. K. (2012). Drug solubility: Importance and enhancement techniques. ISRN Pharmaceutics, 199727, 1–10. https://doi.org/10.3390/cancers15010268
   Google Scholar
• Saleem, U., Bibi, S., Shah, M. A., Ahmad, B., Saleem, A., Chauhdary, Z., Anwar, F., Javaid, N., Hira, S., Akhtar, M. F., Shah, G. M., Khan, M. S., Muhammad, H., & Qasim, M. (2021). Anti-Parkinson’s evaluation of Brassica juncea leaf extract and underlying mechanism of its phytochemicals. Frontiers in Bioscience-Landmark, 26(October), 1031–1051. https://doi.org/10.52586/5007
   PubMedGoogle Scholar
• Salehi, B., Vlaisavljevic, S., Adetunji, C. O., Adetunji, J. B., Kregiel, D., Antolak, H., Pawlikowska, E., Uprety, Y., Mileski, K. S., Devkota, H. P., Sharifi-Rad, J., Das, G., Patra, J. K., Jugran, A. K., Segura-Carretero, A., & Contreras, M. D M. (2019). Plants of the genus Vitis: Phenolic compounds, anticancer properties and clinical relevance. Trends in Food Science & Technology, 91(July), 362–379. https://doi.org/10.1016/j.tifs.2019.07.042
   Google Scholar
• Salman, M. M., Al-Obaidi, Z., Kitchen, P., Loreto, A., Bill, R. M., & Wade-Martins, R. (2021). Advances in applying computer-aided drug design for neurodegenerative diseases. International Journal of Molecular Science, 22, 1–22. https://doi.org/10.1021/jm990129n
   Web of Science ®Google Scholar
• Sarkar, U., & Chattaraj, P. K. (2021). Conceptual DFT based electronic structure principles in a dynamical context. Journal of the Indian Chemical Society, 98(7), 100098. https://doi.org/10.1016/j.jics.2021.100098
   Web of Science ®Google Scholar
• Schiffer, C. A. (2018). Diagnosis and treatment of chronic myeloid leukemia. Neoplastic Diseases of the Blood, 90(10), 49–68. https://doi.org/10.1007/978-3-319-64263-5_5
   Google Scholar
• Schlauderer, F., Lammens, K., Nagel, D., Vincendeau, M., Eitelhuber, A. C., Verhelst, S. H. L., Kling, D., Chrusciel, A., Ruland, J., Krappmann, D., & Hopfner, K. P. (2013). Structural analysis of phenothiazine derivatives as allosteric inhibitors of the MALT1 paracaspase. Angewandte Chemie (International ed. in English), 52(39), 10384–10387. https://doi.org/10.1002/anie.201304290
   PubMed Web of Science ®Google Scholar
• Shah, N. P., Kantarjian, H. M., Kim, D. W., Réa, D., Dorlhiac-Llacer, P. E., Milone, J. H., Vela-Ojeda, J., Silver, R. T., Khoury, H. J., Charbonnier, A., Khoroshko, N., Paquette, R. L., Deininger, M., Collins, R. H., Otero, I., Hughes, T., Bleickardt, E., Strauss, L., Francis, S., & Hochhaus, A. (2008). Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 26(19), 3204–3212. https://doi.org/10.1200/JCO.2007.14.9260
   PubMed Web of Science ®Google Scholar
• Sharma, A., Gupta, N., Orfali, R., Kumar, V., Patel, C. N., Peng, J., & Perveen, S. (2022). Evaluation of the antifungal, antioxidant, and anti-diabetic potential of the essential oil of Curcuma longa leaves from the North-Western Himalayas by in vitro and in silico analysis. Molecules (Basel, Switzerland), 27(22), 7664. https://doi.org/10.3390/molecules27227664
   PubMed Web of Science ®Google Scholar
• Sharma, O., Srivastava, S., Sharma, M., & Malik, R. (2023). Discovery of a new dihydropyrimidinone derivative as a potential haspin kinase inhibitor: Structure-guided insights, in-vitro and molecular dynamics-based validation. ChemistrySelect, 8(35), 1–13. https://doi.org/10.1002/slct.202301233
   Web of Science ®Google Scholar
• Shivanika, C., Deepak Kumar, S., Ragunathan, V., Tiwari, P., Sumitha, A., & Brindha Devi, P. (2022). Molecular docking, validation, dynamics simulations, and pharmacokinetic prediction of natural compounds against the SARS-CoV-2 main-protease. Journal of Biomolecular Structure & Dynamics, 40(2), 585–611. https://doi.org/10.1080/07391102.2020.1815584
   PubMed Web of Science ®Google Scholar
• Smith, D. A., Beaumont, K., Maurer, T. S., & Di, L. (2018). Relevance of half-life in drug design. Journal of Medicinal Chemistry, 61(10), 4273–4282. https://doi.org/10.1021/acs.jmedchem.7b00969
   PubMed Web of Science ®Google Scholar
• Soars, M. G., McGinnity, D. F., Grime, K., & Riley, R. J. (2007). The pivotal role of hepatocytes in drug discovery. Chemico-Biological Interactions, 168(1), 2–15. https://doi.org/10.1016/j.cbi.2006.11.002
   PubMed Web of Science ®Google Scholar
• Sohlenius-Sternbeck, A. K., & Terelius, Y. (2022). Evaluation of ADMET predictor in early discovery drug metabolism and pharmacokinetics project work. Drug Metabolism and Disposition: The Biological Fate of Chemicals, 50(2), 95–104. https://doi.org/10.1124/dmd.121.000552
   PubMed Web of Science ®Google Scholar
• Solo-Aben, O. M. H., Alanko, I., Bhadane, R., Bonvin, A. M. J. J., Honorato, R. V., Hussain, S., Juffer, A. H., Kabedev, A., Lahtela-Kakkomen, M., Larsen, A. S., Lescrinier, E., Marimuthu, P., Mina, M. U., Mustafa, G., Nunes-Alves, A., Panisar, T., Saadabadi, A., Singaravelu, K., & Vanmeert, M. (2021). Molecular dynamics simulations in drug discovery and pharmaceutical development. Processes, 9(71), 1–60. https://doi.org/10.1007/978-3-030-36260-7_10
   Google Scholar
• Stella, S., Gottardi, E. M., Favout, V., Gonzalez, E. B., Errichiello, S., Vitale, S. R., Fava, C., Luciano, L., Stagno, F., Grimaldi, F., Pironi, L., Simarro, C. S., Vigneri, P., & Izzo, B. (2019). The Q-LAMP method represents a valid and rapid alternative for the detection of the BCR-ABL1 rearrangement in Philadelphia-positive leukemias. International Journal of Molecular Sciences, 20(24), 6106. https://doi.org/10.3390/ijms20246106
   PubMed Web of Science ®Google Scholar
• Sun, L., Yang, H., Li, J., Wang, T., Li, W., Liu, G., & Tang, Y. (2018). In silico prediction of compounds binding to human plasma proteins by QSAR models. ChemMedChem. 13(6), 572–581. https://doi.org/10.1002/cmdc.201700582
   PubMed Web of Science ®Google Scholar
• Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., & Bray, F. (2021). Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 71(3), 209–249. https://doi.org/10.3322/caac.21660
   PubMed Web of Science ®Google Scholar
• Tian, H., Ketkar, R., & Tao, P. (2022). ADMETboost: A web server for accurate ADMET prediction. Journal of Molecular Modeling, 28(12), 408. https://doi.org/10.1007/s00894-022-05373-8
   PubMed Web of Science ®Google Scholar
• Tibbitts, J., Canter, D., Graff, R., Smith, A., & Khawli, L. A. (2016). Key factors influencing ADME properties of therapeutic proteins: A need for ADME characterization in drug discovery and development. mAbs, 8(2), 229–245. https://doi.org/10.1080/19420862.2015.1115937
   PubMed Web of Science ®Google Scholar
• Torres, P. H. M., Sodero, A. C. R., Jofily, P., & Silva, F. P. Jr, (2019). Key topics in molecular docking for drug design. International Journal of Molecular Sciences, 20(18), 4574. https://doi.org/10.3390/ijms20184574
   PubMed Web of Science ®Google Scholar
• Tran, Q. H., Nguyen, Q. T., Vo, N. Q. H., Mai, T. T., Tran, T. T. N., Tran, T. D., Le, M. T., Trinh, D. T. T., & Minh Thai, K. (2022). Structure-based 3D-pharmacophore modeling to discover novel interleukin 6 inhibitors: An in silico screening, molecular dynamics simulations and binding free energy calculations. PloS One, 17(4), e0266632. https://doi.org/10.1371/journal.pone.0266632
   PubMed Web of Science ®Google Scholar
• van Mourik, T., Bühl, M., & Gaigeot, M. P. (2014). Density functional theory across chemistry, physics and biology. Philosophical Transactions. Series A, Mathematical, Physical, and Engineering Sciences, 372(2011), 20120488. https://doi.org/10.1098/rsta.2012.0488
   PubMed Web of Science ®Google Scholar
• Veber, D. F., Johnson, S. R., Cheng, H., Smith, B. R., Ward, K. W., & Kopple, K. D. (2002). Molecular properties that influence the oral bioavailability of drug candidates. Journal of Medicinal Chemistry, 45(12), 2615–2623. https://doi.org/10.1021/jm020017n
   PubMed Web of Science ®Google Scholar
• Vlasiou, M. C., & Pafti, K. S. (2021). Screening possible drug molecules for COVID-19. The example of vanadium (III/IV/V) complex molecules with computational chemistry and molecular docking. Computational Toxicology (Amsterdam, Netherlands), 18(January), 100157. https://doi.org/10.1016/j.comtox.2021.100157
   PubMedGoogle Scholar
• Wang, J. B., Cao, D. S., Zhu, M. F., Yun, Y. H., Xiao, N., & Liang, Y. Z. (2015). In silico evaluation of logD7.4 and comparison with other prediction methods. Journal of Chemometrics, 29(7), 389–398. https://doi.org/10.1002/cem.2718
   Web of Science ®Google Scholar
• Wang, R., Zheng, Q. X., Wang, W., Feng, L., Li, H. J., & Huai, Q. Y. (2017). Design and synthesis of new anticancer glycyrrhetinic acids and oleanolic acids. Biological & Pharmaceutical Bulletin, 40(5), 703–710. https://doi.org/10.1248/bpb.b17-00016
   PubMed Web of Science ®Google Scholar
• Weisberg, E., Manley, P. W., Breitenstein, W., Brüggen, J., Cowan-Jacob, S. W., Ray, A., Huntly, B., Fabbro, D., Fendrich, G., Hall-Meyers, E., Kung, A. L., Mestan, J., Daley, G. Q., Callahan, L., Catley, L., Cavazza, C., Azam, M., Neuberg, D., Wright, R. D., Gilliland, D. G., & Griffin, J. D. (2005). Characterization of AMN107, a selective inhibitor of native and mutant BCR-Abl. Cancer Cell, 7(2), 129–141. https://doi.org/10.1016/j.ccr.2005.01.007
   PubMed Web of Science ®Google Scholar
• Wicker, J. G. P., & Cooper, R. I. (2016). Beyond rotatable bond counts: Capturing 3D conformational flexibility in a single descriptor. Journal of Chemical Information and Modeling, 56(12), 2347–2352. https://doi.org/10.1021/acs.jcim.6b00565
   PubMed Web of Science ®Google Scholar
• Williams, J., Siramshetty, V., Nguyễn, Ð.-T., Padilha, E. C., Kabir, M., Yu, K.-R., Wang, A. Q., Zhao, T., Itkin, M., Shinn, P., Mathé, E. A., Xu, X., & Shah, P. (2022). Using in vitro ADME data for lead compound selection: An emphasis on PAMPA pH 5 permeability and oral bioavailability. Bioorganic & Medicinal Chemistry, 56(56), 116588. https://doi.org/10.1016/j.bmc.2021.116588.Using
   PubMedGoogle Scholar
• World Health Organization (WHO). (2023, November 12). WHO reveals leading causes of death and disability worldwide: 2000-2019. Retrieved from https://www.who.int/news/item/09-12-2020-who-reveals-leading-causes-of-death-and-disability-worldwide-2000-2019
   Google Scholar
• Wu, F., Zhou, Y., Li, L., Shen, X., Chen, G., Wang, X., Liang, X., Tan, M., & Huang, Z. (2020). Computational approaches in preclinical studies on drug discovery and development. Frontiers in Chemistry, 8(September), 726. https://doi.org/10.3389/fchem.2020.00726
   PubMedGoogle Scholar
• Yuan, M., Zhang, G., Bai, W., Han, X., Li, C., & Bian, S. (2022). The role of bioactive compounds in natural products extracted from plants in cancer treatment and their mechanisms related to anticancer effects. Oxidative Medicine and Cellular Longevity, 2022, 1429869. https://doi.org/10.1155/2022/1429869
   PubMed Web of Science ®Google Scholar
• Zarrouk, A., Assouag, M., Zarrok, H., Oudda, H., Bentiss, F., Touzani, R., Hammouti, B., Bouachrine, M., & August, J. (2015). Theoretical study of a new group of corrosion inhibitors. Research Journal of Pharmaceutical, Biological and Chemical Sciences, 6(4), 1874–1882. https://doi.org/10.1021/jp052188k
   Google Scholar
• Zhang, H., Mu, Y., Wang, F., Song, L., Sun, J., Liu, Y., & Sun, J. (2018). Synthesis of gypsogenin derivatives with capabilities to arrest cell cycle and induce apoptosis in human cancer cells. Royal Society Open Science, 5(1), 171510. https://doi.org/10.1098/rsos.171510
   PubMed Web of Science ®Google Scholar
• Zhang, Y., Wu, J., Jin, W., Shen, M., Yin, S., Lai, X., Ma, H., Jiang, M., Sun, D., & Yan, J. (2022). Nonreceptor tyrosine kinase c-Abl-mediated PHB2 phosphorylation aggravates mitophagy disorder in Parkinson’s disease model. Oxidative Medicine and Cellular Longevity, 2022, 9233749. https://doi.org/10.1155/2022/9233749
   PubMed Web of Science ®Google Scholar